Latest Breaking News On - மொழிபெயர்ப்பு கண்டுபிடிப்பு - Page 1 : comparemela.com
I-Corps@NCATS Course Positions Medical Innovations for Success
northwestern.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from northwestern.edu Daily Mail and Mail on Sunday newspapers.
Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer
sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.
Staff Profile: Alexandra de Paz, Assistant Director of New Ventures
If you ask Alexandra de Paz, PhD, she’ll tell you that a love for translational thinking seems to be familial. Her own excitement for new technologies grew following her sister’s interdisciplinary learning experiences at the Massachusetts Institute of Technology.
“Listening to my sister talk about her work was like listening to really evolved science fiction and I was completely hooked,” says de Paz, assistant director of the New Ventures at the Innovation and New Ventures (INVO) Office and Northwestern University Clinical and Translational Sciences (NUCATS) Institute.
INVO and NUCATS operate the shared Center for Translational Innovation, which serves to catalyze the translation of Northwestern innovations to benefit the public and promote economic growth. INVO is dedicated to working with faculty and students across Northwestern’s Chicago and Evanston campuses, as well as local partners at Ann & Robert
E-Mail
-AGREEMENT ADVANCES EVOLUTION OF SYNTHETIC LUNG SURFACTANTS TO TREAT RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS IN LOW- AND MIDDLE-INCOME COUNTRIES-
LOS ANGELES (March 8, 2021) The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
Newborns experiencing RDS must dramatically increase the effort to take each breath, due to lack of adequate, naturally-occurring surfactant production in their lungs. This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated. The standard of care is injecting naturally-occurring surfactant, normally animal-deriv
In-licensed candidate may be an effective intervention for premature infants with respiratory distress syndrome
The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC).
TLI already maintains patents on this invention in the United States, Canada and Europe. Newborns experiencing RDS must dramatically increase the effort to take each breath, due to lack of adequate, naturally-occurring surfactant production in their lungs.
This deficiency of lung surfactant leads to fatigue, episodes of apnea, hypoxia, wasting, and potentially death if untreated. The standard of care is injecting naturally-occurring surfactant, normally animal-derived, into the lungs of preterm babies a definitive treatment that is lifesaving, but i
vimarsana © 2020. All Rights Reserved.